Posts by category
- Category: In The News
- Category: News
- Category: Presentations
- Category: Publications
- Hioe et al. (2026) “An HIV V1V2 mRNA-LNP vaccine induces strong, cross-clade functional antibody responses in mice and rhesus macaques” Journal of Immunology.
- Marchitto et al. (2026) “Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies” Nature.
- Krooss et al. (2026) “LNP-mediated base editing reduces hepatic iron overload and modifies fibrosis- and HCC-associated gene expression in HFE-related hemochromatosis mice” Journal of Hepatology.
- Cohen et al. (2026) “mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures” Cell Reports.
- Tálas et al. (2026) “RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I” Science Translational Medicine.
- Dosey et al. (2026) “Stabilization of the H5 clade 2.3.4.4b hemagglutinin improves vaccine-elicited neutralizing antibody responses in mice” Science Translational Medicine.
- Oyedele et al. (2026) “A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial” Vaccine.
- Castaño et al. (2025) “Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses” Cell.
- Laliberte et al. (2025) “Immunogenicity and efficacy of an mRNA vaccine expressing a virus-like particle spike antigen against SARS-CoV-2” NPJ Vaccines.
- Yengo et al. (2025) “Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations” Frontiers in Immunology.
- Styles et al. (2025) “Chimeric hemagglutinin-based universal influenza mRNA vaccine induces protective immunity and bone marrow plasma cells in rhesus macaques” Cell Reports Medicine.
- Lawtrakulngam et al. (2025) “Enhancing osseointegration with LNP-delivered mRNA–encoded BMP-2: An experimental in vivo study” Clinical Oral Implants Research.
- Hendricks et al. (2025) “Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice” Science Translational Medicine.
- Janjuha et al. (2025) “Spatial profiling of gene editing by in situ sequencing in mice and macaques” Nature Biomedical Engineering.
- Limsalakpetch et al. (2025) “mRNA-LNP vaccine encoding the Plasmodium vivax circumsporozoite protein is highly immunogenic and confers protection in mice” Molecular Therapy Nucleic Acids.
- Limeres et al. (2025) “mRNA-LNP vaccines against hepatitis B virus induce protective immune responses in preventive and chronic mouse challenge models” Molecular Therapy.
- Shuvaev et al. (2025) “Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo” PNAS.
- Surisaeng et al. (2025) “BMP-2 mRNA-transfected BMSCs promote superior calvarial bone regeneration” Scientific Reports.
- Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
- Acuitas Therapeutics named one of BC’s Top Employers of 2025
- Tremblay et al. (2025) “A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels” Nature Medicine.
- PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
- Imiolek et al. (2025) “High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays” Analytical Chemistry.
- PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
- Banda et al. (2025) “Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles” Molecular Therapy.
- Smith et al. (2024) “Impact of metabolic states on SARS-CoV-2 vaccine responses in mouse models of obesity and diabetes” MDPI.
- Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
- Abt et al. (2024) “Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire” PNAS.
- Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
- Acuitas Therapeutics Honoured With Philanthropic Award
- Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
- Castruccio Castracani et al. (2024) “An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA” Blood.
- Chappell et al. (2024) “Use of HSC targeted LNP to generate a mouse model of lethal α-Thalassemia and treatment via lentiviral gene therapy” Blood.
- Leonard et al. (2024) “Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA” Nature Communications.
- PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
- Cohen et al. (2024) “Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals” Cell.
- Alameh et al. (2024) “A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection” Science.
- Atochina-Vasserman et al. (2024) “Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection” NPJ Vaccines.
- Kafle et al. (2024) “The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines” Molecular Therapy Nucleic Acids.
- Kuzmin et al. (2024) “Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine” Nature Communications.
- Guenaga et al. (2024) “mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies” Frontiers in Immunology.
- Christopher Sweeney Named Executive Director, Intellectual Property
- England et al. (2024) “Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model” NPJ Vaccines.
- Smith et al. (2024) “Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice” Nature Communications.
- Parhiz et al. (2024) “Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system” Molecular Therapy Nucleic Acids.
- Montoya et al. (2024) “mRNA-LNP vaccine-induced CD8+ T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies” Molecular Therapy.
- Furey et al. (2024) “Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus” Nature Communications.
- Wiehe et al. (2024) “Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction” Cell Host & Microbe.
- Acuitas Poster Presentations at ASGCT Annual Meeting
- Nong et al. (2024) “Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke” Molecular Therapy.
- Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024
- Tafech et al. (2024) “Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions” Advanced Healthcare Materials.
- Tilsed et al. (2024) “IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation” PNAS.
- Birdsall et al. (2024) “Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs” Journal of ChromatographyB.
- Acuitas Therapeutics Named One of BC’s Top Employers of 2024
- Matias et al. (2024) “mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis” Scientific Reports.
- Kunkeaw et al. (2023) “A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax” NPJ Vaccines.
- Breda et al. (2023) “In vivo hematopoietic stem cell modification by mRNA delivery” Science.
- Hoffmann et al. (2023) “ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines” Cell.
- Gál et al. (2023) “Restoration of motor function through delayed intraspinal delivery of human IL-10-encoding nucleoside-modified mRNA after spinal cord injury” Research.
- Connors et al. (2023) “Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals” Communications Biology.
- Schiepers et al. (2023) “Molecular fate-mapping of serum antibody responses to repeat immunization” Nature.
- Arevalo et al. (2022) “A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes” Science.
- Gorsuch et al. (2022) “Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo” Molecular Therapy.
- Pardi et al. (2022) “Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses” Nature Communications.
- Mu et al. (2022) “mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice” Cell Reports.
- Rurik et al. (2022) “CAR T cells produced in vivo to treat cardiac injury” Science.
- Mallory et al. (2021) “Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice” NPJ Vaccines.
- Musunuru et al. (2021) “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” Nature.
- Rothgangl et al. (2021) “In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels” Nature Biotechnology.
- Rizvi et al. (2021) “Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA” Nature Communications.
- Villiger et al. (2021) “In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA” Nature Biomedical Engineering.
- Weissman et al. (2021) “D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization” Cell Host & Microbe.
- Lederer et al. (2020) “SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation” Immunity.
- Laczkó et al. (2020) “A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice” Immunity.
- McKay et al. (2020) “Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice” Nature Communications.
- Freyn et al. (2020) “A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice” Molecular Therapy.
- Raj et al. (2020) “Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria” Nature.
- Marcos-Contreras (2020) “Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier” PNAS.
- Willis et al. (2020) “Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice” Science Translational Medicine.
- Huysmans et al. (2019) “Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin” Molecular Therapy Nucleic Acids.
- Pardi et al. (2019) “Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques” Molecular Therapy Nucleic Acids.
- Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Molecular Therapy.
- Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” Journal of Controlled Release.
- Pardi et al. (2018) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies” Nature Communications.
- Pardi et al. (2018) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine.
- Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines.
- Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
- Pardi et al. (2017) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications.
- Pardi et al. (2017) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature.
- Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” Journal of Controlled Release.
- Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Molecular Therapy.
- Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Molecular Therapy.
- Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Molecular Therapy Nucleic Acids.
- Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angewandte Chemie.
- Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Molecular Therapy.
- Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology.
Topics